BioLineRx to Host Investor and Analyst Breakfast Meeting on December 11, 2018 in New York

News provided by

Dec 06, 2018, 07:00 ET

TEL AVIV, Israel, December 6, 2018 /PRNewswire/ --

BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will host an investor breakfast meeting on Tuesday, December 11, 2018 at the Convene Conference Center near Grand Central Terminal in New York, N.Y.

The investor meeting schedule is as follows:

7:45 am EST - Registration and breakfast
8:10-9:30 am EST - Formal presentations

Location:

Convene Conference Center
101 Park Avenue South (near Grand Central Terminal)
New York, N.Y.
(888) 730-7307

The event will feature presentations by Ezra Cohen, MD, FRCPSC, FASCO, from UC San Diego, who will discuss the progress made in the clinical development of immunotherapies beyond checkpoint inhibitors; and Manuel Hidalgo, MD, PhD, from Beth Israel Deaconess Medical Center, Harvard Medical School, on the unmet medical need in treating patients with pancreatic cancer. Both KOLs will be available to answer questions at the conclusion of the event.

BioLineRx's management team will provide an update on the Company's clinical development of BL-8040 and AGI-134, as well as a review of recent corporate achievements and the Company's strategy for 2019. BL-8040 is a short peptide that functions as a high-affinity antagonist for CXCR4 in late clinical development for the treatment of solid tumors, acute myeloid leukemia (AML) and stem-cell mobilization for bone-marrow transplantation. AGI-134 is a synthetic αGal novel immunotherapy currently in Phase 1/2a development for solid tumors.

Ezra Cohen, MD, is co-Director of the San Diego Center for Precision Immunotherapy and an internationally renowned translational researcher. A physician-scientist, his recent National Institutes of Health-funded work in the study of epidermal growth factor receptor inhibitors in head and neck cancer has contributed to the understanding of the biology of this critical signaling network, integration of these agents into standard of care, and definition of mechanisms to overcome resistance. He recently served as chair of the NCI Head and Neck Cancer Steering Committee that oversees NCI-funded clinical research (including all NCI Cooperative Group trials) in this disease. Dr. Cohen is also Associate Director for Translational Science and leader of the Solid Tumor Therapeutics research program at Moores Cancer Center. Among other roles, he is chair of the Protocol Review and Monitoring Committee (PRMC) and serves as a member of the Cancer Council, and the Cancer Center's Executive Committee. He has also been the principal investigator on multiple studies of novel agents in head and neck cancer and other solid tumors in all phases of development. Dr. Cohen recently served as editor-in-chief of Oral Oncology.

Manuel Hidalgo, MD, PhD, is Director of the Leon V. & Marilyn L. Rosenberg Clinical Cancer Center and Chief of the Division of Hematology-Oncology at Beth Israel Deaconess Medical Center (BIDMC). He is also the Theodore W. and Evelyn G. Berenson Professor of Medicine at Harvard Medical School. An internationally renowned oncologist, Dr. Hidalgo is a world leader in the testing and development of new agents for pancreatic and other solid tumor cancers. He oversees all BIDMC clinical cancer programs. Dr. Hidalgo is a founder of the Pancreatic Cancer Research Team (PCRT), a private nonprofit cooperative group dedicated to rapid drug development in pancreatic cancer. He is a former member of the Science Committee of Cancer Research UK and a member of the Special Conferences Committee of the American Association of Cancer Research and Scientific Advisory Board of Pancreatic Cancer Action Network. He is also the Director of the Vail Course "Methods on Clinical Cancer Research." Dr. Hidalgo is scientific editor of Cancer Discovery.

This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. For those who are unable to attend in person, a live webcast and replay of the event will be accessible here. If you would like to ask a question during the live Q&A portion of the event, please submit your request via email.

About BioLineRx

BioLineRx is a clinical-stage biopharmaceutical company focused on oncology and immunology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory AML, is in the midst of a Phase 2b study as an AML consolidation treatment and has initiated a Phase 3 study in stem cell mobilization for autologous transplantation; and AGI-134, an immunotherapy treatment in development for multiple solid tumors, which has recently initiated a Phase 1/2a study. In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates; a collaboration agreement with MSD, on the basis of which the Company is conducting a Phase 2a study in pancreatic cancer using the combination of BL-8040 and KEYTRUDA^® (pembrolizumab), and a collaboration agreement with Genentech, a member of the Roche Group, to investigate the combination of BL-8040 and Genentech's atezolizumab in several Phase 1b/2 studies for multiple solid tumor indications and AML.

For additional information on BioLineRx, please visit the Company's website at www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook, Twitter, and LinkedIn.

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 6, 2018. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.